Multifunctional Graphene Oxide Nanodelivery Platform for Breast Cancer Treatment
Yousheng Mo,Wei Liu,Piaoxue Liu,Qiao Liu,Zhongyu Yuan,Qi Wang,Dongsheng Yuan,Xiao-Jia Chen,Tongkai Chen
DOI: https://doi.org/10.2147/ijn.s380447
IF: 7.033
2022-12-15
International Journal of Nanomedicine
Abstract:Yousheng Mo, 1, &ast Wei Liu, 2, &ast Piaoxue Liu, 2 Qiao Liu, 3 Zhongyu Yuan, 4 Qi Wang, 2 Dongsheng Yuan, 2 Xiao-Jia Chen, 3 Tongkai Chen 2 1 The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, People's Republic of China; 2 Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China; 3 State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, People's Republic of China; 4 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiao-Jia Chen; Tongkai Chen, Email ; Background: Breast cancer (BC) has the highest global prevalence among all malignancies in women and the second highest prevalence in the overall population. Paclitaxel (PTX), a tricyclic diterpenoid, is effective against BC. However, its poor solubility in water and the allergenicity of its dissolution medium limited its clinical application. Methods: In this work, we established a multifunctional graphene oxide (GO) tumor-targeting drug delivery system using nanosized graphene oxide (nGO) modified with D-tocopherol polyethylene glycol succinate (TPGS) and arginine-glycine-aspartic acid (RGD) for PTX loading. Results: The obtained RGD-TPGS-nGO-PTX was 310.20± 19.86 nm in size; the polydispersity index (PDI) and zeta potential were 0.21± 0.020 and − 23.42 mV, respectively. The mean drug loading capacity of RGD-TPGS-nGO-PTX was 48.78%. RGD-TPGS-nGO-PTX showed satisfactory biocompatibility and biosafety and had no significant toxic effects on zebrafish embryos. Importantly, it exerted excellent cytotoxicity against MDA-MB-231 cells, reversed multi-drug resistance (MDR) in MCF-7/ADR cells, and showed significant anti-tumor efficacy in tumor-bearing nude mice. Conclusion: These findings strongly suggested that the multifunctional GO tumor-targeting drug delivery system RGD-TPGS-nGO-PTX could be used in clinical settings to improve PTX delivery, reverse MDR and increase the therapeutic efficacy of BC treatment. Keywords: breast cancer, paclitaxel, targeted delivery, multidrug resistance Breast cancer (BC) has the highest global prevalence among all malignancies in women and the second highest prevalence in the overall population. 1 The most common therapeutic strategies for BC conservative surgery, radiation therapy, and chemotherapy cause several adverse effects, including lymphedema, damage to normal tissue, and tumor recurrence. 2–4 Pharmacological strategies are indispensable to accessible and effective treatments for BC patients. 5,6 Nevertheless, the drugs currently used to treat BC have unsatisfactory efficacy due to poor tumor targeting and drug resistance. 7,8 Therefore, new strategies must be explored for improving drug efficacy and targeting, overcoming drug resistance, and reducing off-target toxicity. Nanomedicine has entered the field of view of researchers for its excellent targeted therapeutic properties. The known nanocarriers for targeted therapy of breast cancer include albumin-coated copper nanoparticles (ACuNPs), 9 chitosan/carbon quantum dot/aptamer complex (CS-CQD-apt), 10 agarose-polyethylene pyridoxanidone-hydroxyapatite (AG-PVP-Hap) 11 and many other nanocarriers. In addition, a variety of novel nanomaterials with excellent performance have been developed to significantly enhance the bioavailability, biocompatibility, and tumor targeting of natural compounds such as curcumin 12 and sesamol. 13,14 Graphene oxide (GO), an oxidized form of graphene, has recently been developed as a novel two-dimensional carbon nanomaterial. 15 It has received extensive attention in drug delivery studies due to their good biocompatibility and low toxicity. 16,17 The surface of GO has hydrophilic groups, including hydroxyl (–OH), carboxyl (–COOH) and methoxyl (CH 3 O-) groups, which can be modified and biofunctionalized. 18 Furthermore, nanosized GO (nGO) possesses good dispersity in water and also has a smaller particle size and good stability. 19 Importantly, nGO has a high drug loading capacity and excellent photothermal conversion performance and is easy to prepare. 20 One major challenge in the efficient treatment of cancer i -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology